Search Press Releases

 Search

COPD Foundation Hosts “COPD Annual Awards Celebration” to Recognize Influential Community Stakeholders

October 06, 2017   |   
I Care 5 Cares

WASHINGTON, D.C. - October 6, 2017 - The COPD Foundation, a nonprofit organization dedicated to curing chronic obstructive pulmonary disease (COPD), has announced the details around its annual fundraiser. The COPD Annual Awards Celebration will be held November 2, 2017 at the Metropolitan Club in New York City from 6:30-9:30 p.m. The ceremony, hosted by COPD Foundation Board chairman Dr. Byron Thomashow, will pay tribute to individuals and organizations whose work has paved the way for COPD advocacy, research, and community building in 2017.

The Honorees are:

  • John W. Walsh Visionary Award: Gerard M. Turino, M.D.
  • Champion for COPD Award: Constance J. Milstein
  • COPD Advocacy Award: Karen Deitemeyer
  • COPD Awareness Award: FCB Health

Read More

Tags: Annual Awards Ceremony COPD gala

Barbara Yawn, MD named Chief Scientific Officer of COPD Foundation

September 29, 2017   |   
I Care 12 Cares

WASHINGTON, D.C. – September 29, 2017 – The COPD Foundation announced today that Barbara Yawn, MD has joined the organization as Chief Scientific Officer. Dr. Yawn comes with 25 years of experience as a primary care researcher with a focus in respiratory disease, specifically asthma and chronic obstructive pulmonary disease (COPD). Additionally, she brings 14 years of full-time rural family medicine practice as well as training in research design and statistics. Dr. Yawn succeeds Dr. David Mannino in the role and will provide clinical oversight of the COPD Foundation’s overall research agenda going forward.

“Dr. Yawn is exceptionally well qualified to serve as the COPD Foundation’s chief scientific officer. She has been involved with the COPD Foundation since inception, including serving on the Foundation’s Medical and Scientific Advisory Committee (MASAC). As a primary care physician, Dr. Yawn has provided a unique and critical perspective,” says Craig Kephart, the COPD Foundation’s chief executive officer.

Read More

Tags: Barbara Yawn Chief Scientific Officer COPD

GSK and Innoviva report positive headline results from IMPACT study showing single inhaler triple therapy Trelegy Ellipta reduced COPD exacerbations

September 20, 2017   |   
I Care 2 Cares

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. today announced positive headline results from the landmark phase III IMPACT study of Trelegy Ellipta, the first and only FDA approved once-daily single inhaler triple therapy comprising an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA) and long-acting beta agonist (LABA). Trelegy Ellipta is approved for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) who are receiving Breo and require additional bronchodilation or who are receiving Breo and Incruse.

Read More

Tags: GSK Trelegy Ellipta

Trelegy Ellipta approved as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US

September 19, 2017   |   
I Care 2 Cares

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), under the brand name Trelegy Ellipta, for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, who are on a fixed-dose combination of fluticasone furoate and vilanterol for airflow obstruction and reducing exacerbations in whom additional treatment of airflow obstruction is desired or for patients who are already receiving umeclidinium and a fixed-dose combination of fluticasone furoate and vilanterol. Trelegy Ellipta is not indicated for relief of acute bronchospasm or the treatment of asthma.

Read More

Tags: FDA Trelegy Ellipta

National Heart, Lung, and Blood Institute Division of Lung Disease, Airway Biology and Disease Branch Awarded Inaugural John W. Walsh Award

August 03, 2017   |   
I Care 11 Cares

Washington, DC - August 3, 2017 - The COPD Foundation announced that four members of the National Institutes of Health's National Heart, Lung, and Blood Institute (NHLBI) Division of Lung Disease, Airway Biology and Disease Branch were awarded the "2017 John W. Walsh Award for Advocacy on Behalf of COPD" at its COPD10usa conference in Chicago, IL on Saturday, July 26. This inaugural award was given on behalf of the COPD Conferences (UK and USA) that are committed to recognizing individuals who have made an outstanding contribution in the field of chronic obstructive pulmonary disease (COPD). Inductees are admitted to the COPD Hall of Fame.

Read More

Tags: conference COPD Hall of Fame National Action Plan NHLBI

COPD10usa Conference in Chicago Highlights Latest Clinical, Scientific and Care Delivery

June 29, 2017   |   
I Care 8 Cares

WASHINGTON, D.C./CHICAGO - June 29, 2017 - The COPD Foundation will host COPD10usa, July 28-29 2017, at Hyatt Regency O’Hare, Chicago. The event will focus on chronic obstructive pulmonary disease (COPD), the nation's third leading cause of death, providing clinical and scientific knowledge for physicians, nurses, respiratory therapists and anyone involved with the management of individuals with COPD.

Read More

Tags: Chicago conference COPD Patient Workshop

COPD Foundation Launches COPD and Pneumonia Study to Recognize the Burden of Pneumonia on Patients

June 26, 2017   |   
I Care 11 Cares

Washington, D.C. - June 26, 2017 - The COPD Foundation today announced the launch of the COPD and Pneumonia Study (CAP), a research initiative designed to describe the burden of pneumonia on individuals living with chronic obstructive pulmonary disease (COPD). COPD, a progressive lung disease characterized by wheezing and breathlessness, affects 30 million Americans. An acute lung infection, such as pneumonia, is potentially fatal for those living with COPD. The CAP study aims to provide the scientific community with evidence of pneumonia’s impact from the perspective of affected patients.

The CAP study is a multi-stakeholder project comprised of a series of online surveys. The project will expand upon past studies measuring the impact of pneumonia on the general population, but have not specifically observed high risk populations such as those living with COPD. It will address these limitations by utilizing a patient-reported outcomes instrument called CAP-Burden of Illness Questionnaire (CAP-BIQ) as the baseline and for the longitudinal components.

Read More

Tags: COPD and Pneumonia Pneumonia Study Survey

Insmed Funds Expansion of COPD Foundation Bronchiectasis and NTM Research Registry

June 14, 2017   |   
I Care 9 Cares

WASHINGTON, D.C. - June 14, 2017 - The COPD Foundation announced today a grant award from Insmed, Inc. to expand the Bronchiectasis and NTM Research Registry. The Registry is a consolidated database of non-cystic fibrosis Bronchiectasis (NCFB) and/or Nontuberculous Mycobacterium (NTM) patients from multiple clinical institutions across the United States. The goal of the Registry is to support collaborative research and assist in the planning of clinical trials for the treatment of non-CF Bronchiectasis and/or NTM lung disease. Expansion plans include enrollment of 1,200 new patients into the Registry and the addition of at least two new Consortium sites.

Read More

Tags: Bronchiectasis non-cystic fibrosis Bronchiectasis Nontuberculous Mycobacterium (NTM)

The COPD Foundation Joins the National Effort to Reduce the Burden of COPD

May 22, 2017   |   
I Care 9 Cares

Washington, D.C. - May 22, 2017 - The National Institutes of Health in a collaborative effort with representatives from across the entire COPD community released the COPD National Action Plan. This first-of-its-kind document provides a unified framework to guide stakeholders nationwide in their efforts to work together to positively impact the effect of the disease

The COPD National Action Plan follows the COPD Town Hall held in 2016 where patients, caregivers, government representatives, and medical professionals convened to address the disparities in government funding of prevention, treatment, and research around chronic obstructive pulmonary disease (COPD). The COPD Foundation has long advocated for the need to create a comprehensive Action Plan to tackle the national epidemic. COPD is a lung disease characterized by an increasing inability to breathe and is the third leading cause of death in the U.S.

Read More

Tags: COPD National Action Plan

COPD Foundation Wins “Best In Air” Award for Dedication to Reducing Regional Air Pollution

May 17, 2017   |   
I Care 9 Cares

WASHINGTON, D.C. - May 17, 2017 - Regional air quality organization Clean Air Partners celebrated 20 years of dedication to improving the greater Baltimore-Washington region’s air quality at last night’s Annual Awards Celebration. Clean Air Partners has reinvigorated the celebration with the Best In Air Awards, honoring industry leaders COPD Foundation, Grid Alternatives, and Lyft for their exemplary commitment to decreasing air pollution and protecting public health. The Awards also recognized middle and high school students for their outstanding creativity as part of the On the Air education awards. The full list of Award winners can be found at www.cleanairpartners.net.

“This is a celebratory year for Clean Air Partners – you don’t turn 20 twice," says Jennifer Desimone of Clean Air Partners. “We wanted to take it up a notch and commend organizations and companies for their commitment to improving our region’s air quality and protecting the health of our residents. We nominated nearly 20 organizations and opened it up to public voting – we are honored to have the support from the incredible winners.”

The Most Valuable Partner (MVP) Award recognizes an organization that has made significant efforts to promote everyday actions to reduce air pollution and the impacts they have on climate change and public health. After a four week public voting period, the COPD Foundation secured the most votes in the MVP category.

Read More

Tags: air quality clean air COPD lung health

COPD Foundation and American Lung Association Collaborate to Enhance COPD Research

April 26, 2017   |   
I Care 10 Cares

Washington, D.C. - April 26, 2017 - The COPD Foundation and American Lung Association today announced a partnership to help more patients living with chronic obstructive pulmonary disease (COPD) access clinical trials, and as a result enhance COPD research and outcomes.

The nation’s third leading cause of death, COPD is a condition that encompasses emphysema, chronic bronchitis, and other diseases characterized by increased breathlessness and wheezing. Through the coordination of the COPD Foundation’s COPD Patient-Powered Research Network (COPD PPRN) and the Lung Association’s Airways Clinical Research Centers (ACRC), both organizations are aiming to improve the quality of life for those living with disease.

The COPD Patient-Powered Research Network (COPD PPRN) is comprised of patients who have provided health and quality of life information using a robust technological infrastructure that supports clinical studies and surveys. The platform provides a unique opportunity for researchers to connect directly with participants, and is overseen by a patient-led governing board to ensure that patient priorities remain at the forefront.

Read More

Tags: American Lung Association Clinical Research COPD

COPD Foundation Establishes JW Walsh Memorial Fund

March 22, 2017   |   
I Care 11 Cares

WASHINGTON, D.C. - March 22, 2017 - The COPD Foundation is proud to announce the establishment of the JW Walsh Fund to Cure COPD in honor of our late founder and director emeritus, John W. Walsh. John recently passed away on March 7, 2017. The memorial fund was created as a way to honor John’s commitment to the mission of the Foundation which strives to find a cure for chronic obstructive pulmonary disease (COPD), the third leading cause of death within the United States.

John’s family has requested that donations in his memory be made to the JW Walsh Fund to Cure COPD, which will be administered by the Foundation.

John’s voice changed the way research studies are designed and executed, the way industry views the patient voice, and even changed the way patients are integrated into medical education. John dedicated much of his life to his commitment to speeding the development of new therapies and a cure for COPD. The COPD Foundation remains strongly committed to furthering John’s passion to engage, educate, and empower patients, helping to improve their lives as it searches for a cure.

Read More

Tags: Fund John W. Walsh JW Walsh Memorial Fund Memorial

1 2 3 4 5 6 7 8 9 10 ... 21

Join Us on COPD360social

Sign In to Participate
Or register to become a member
Medication